Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer
PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl V.P., Groothuis-Oudshoorn Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Read More
Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer
PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar Read More
Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics GalleryConstructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics
Evidence, Health Economics, International Journal of Technology Assessment in Health Care, MammaPrint, Retèl
Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics
PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: Read More
